Targeting FGFR in Squamous Cell Carcinoma of the Lung

Neda Hashemi-Sadraei, Nasser Hanna

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Unlike for adenocarcinomas of the lung, no molecular targeted therapies have yet been developed for squamous cell lung cancers, because targetable oncogenic aberrations are scarce in this tumor type. Recent discoveries have established that the fibroblast growth factor (FGF) signaling pathway plays a fundamental role in cancer development by supporting tumor angiogenesis and cancer cell proliferation via different mechanisms. Through comprehensive genomic studies, aberrations in the FGF pathway have been identified in various tumor types, including squamous cell lung cancer, making FGF receptor (FGFR) a potentially druggable target in this malignancy. Several multi-targeted tyrosine kinase inhibitors include FGFR in their target spectrum and a number of these compounds have been approved for clinical use in different cancers. Novel agents selectively targeting FGFRs have been developed and are currently under investigation in clinical trials, showing promising results. This article reviews FGFR aberrations and the clinical data involving selective and multikinase FGFR inhibitors in squamous cell lung cancer.[Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalTargeted Oncology
DOIs
StateAccepted/In press - Jul 6 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Targeting FGFR in Squamous Cell Carcinoma of the Lung'. Together they form a unique fingerprint.

  • Cite this